Renal impairment and clinical outcomes of clostridium difficile infection in two randomized trials

American Journal of Nephrology

Volumn 38, Issue 1, 2013, Pages 1-11

  Mullane, Kathleen M ^a   Cornely, Oliver A ^d   Crook, Derrick W ^e   Golan, Yoav ^b   Louie, Thomas J ^f   Miller, Mark A ^g   Josephson, Michelle A ^a   Gorbach, Sherwood L ^b,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c Optimer Pharmaceuticals Inc   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CALGARY   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

Clostridium difficile infection; Clostridium difficile associated diarrhea; Fidaxomicin; Renal impairment; Vancomycin

Indexed keywords

FIDAXOMICIN; VANCOMYCIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; TREATMENT RESPONSE; VERY ELDERLY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEVER; FOLLOW UP; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; MORTALITY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; RECURRENCE RISK;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84879188071     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000351757     Document Type: Article

References (32)

1. D'Agata EM, Mount DB, Thayer V, Schaffner W: Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000; 35: 1083-1088.
2. Dial S, Kezouh A, Dascal A, Barkun A, Suissa S: Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008; 179: 767-772.
3. Yousuf K, Saklayen MG, Markert RJ, Barde CJ, Gopalswamy N: Clostridium difficile -associated diarrhea and chronic renal insufficiency. South Med J 2002; 95: 681-683.
4. Pant C, Madonia P, Minocha A, Manas K, Jordan P, Bass P: Laboratory markers as predictors of mortality in patients with Clostridium difficile infection. J Investig Med 2010; 58: 43-45.
5. Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dube S, Vasilevsky CA, McFadden N, Patino C, Labbe AC: Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. Dis Colon Rectum 2009; 52: 400-405.
6. Arrich J, Sodeck GH, Sengolge G, Konnaris C, Mullner M, Laggner AN, Domanovits H: Clostridium difficile causing acute renal failure: case presentation and review. World J Gastroenterol 2005; 11: 1245-1247.
7. Oud L: Intra-abdominal hypertension in fulminant Clostridium difficile infection -an under-recognized treatable complication. Med Sci Monit 2010; 16:CS110-CS113.
8. Dobson G, Hickey C, Trinder J: Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med 2003; 29: 1030.
9. Parmar A, Langenberg C, Wan L, May CN, Bellomo R, Bagshaw SM: Epidemiology of septic acute kidney injury. Curr Drug Targets 2009; 10: 1169-1178.
10. Bauer MP, Kuijper EJ, van Dissel JT: European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079.
11. Crook DW, Walker AS, KeanY, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE: Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 2012; 55(suppl 2):S93-S103.
12. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S: Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-289.
13. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK: Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.
14. Levey AS, Josef Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
15. Betjes MGH: Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 2013; 9: 255-265.
16. Vaziri ND, Pahl MV, Crum A, Norris K: Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22,1: 149-156.
17. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007; 20: 440-451.
18. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm, B: Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008; 3: 1526-1533.
19. Aseeri M, Schroeder T, Kramer J, Zackula R: Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile -associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308-2313.
20. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison LH: A large outbreak of Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-280.
21. Barany P, Stenvinkel P, Nord CE, Bergstrom J: Clostridium difficile infection -a poor prognostic sign in uremic patients? Clin Nephrol 1992; 38: 53-57.
22. Eddi R, Malik MN, Shakov R, Baddoura WJ, Chandran C, Debari VA: Chronic kidney disease as a risk factor for Clostridium difficile infection. Nephrology (Carlton) 2010; 15: 471-475.
23. Daniel K, Cason CL, Shrestha S: A comparison of glomerular filtration rate estimating equation performance in an older adult population sample. Nephrol Nurs J 2011; 38: 351-356.
24. Pai MP: Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010; 17:e53-e62.
25. Sears P, Crook DW, Louie TJ, Miller MA, Miller MA, Weiss K: Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 2012; 55(suppl 2):S116-S120.
26. Thompson CM Jr, Long SS, Gilligan PH, Prebis JW: Absorption of oral vancomycin -possible associated toxicity. Int J Pediatr Nephrol 1983; 4: 1-4.
27. Chihara S, Shimizu R, Furukata S, Hoshino K: Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. Scand J Infect Dis 2011; 43: 149-150.
28. Rao S, Kupfer Y, Pagala M, Chapnick E, Tess ler S: Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis 2011; 43: 386-388.
29. Do AN, Fridkin SK, Yechouron A, Banerjee SN, Killgore GE, Bourgault AM, Jolivet M, Jarvis WR: Risk factors for early recurrent Clostridium difficile -associated diarrhea. Clin Infect Dis 1998; 26: 954-959.
30. Gaughan WJ, Hassan MH, McCue PA, Burke JF, Sharma, K: Association of IgA nephropathy with Clostridium difficile colitis. Am J Kidney Dis 1999; 34:e16.
31. Stewart DB, Hollenbeak CS: Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. J Gastrointest Surg 2011; 15: 1548-1555.
32. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, Sarma JB: Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 2011; 79: 359-363.